Loading
A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas is a phase 1 interventional study registered as NCT06961565 by Pasithea Therapeutics Corp., with 56 participants planned, started 2025-05-30. Conditions recorded: NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) and Neurofibromatosis Type 1 (NF1). Interventions recorded: PAS-004 Tablets and PAS-004 Capsule.
Shares PAS-004, Pasithea Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/